Scientific considerations of forced degradation studies in anda submissions

Pharmaceutical Technology

Volumn 36, Issue 5, 2012, Pages 73-80

  Maheswaran, Ragine ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG DEGRADATION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG POTENCY; DRUG PURITY; DRUG QUALITY; DRUG STABILITY; OXIDATION; PHOTOLYSIS; TEMPERATURE STRESS; THERMOSTABILITY;

EID: 84870028637     PISSN: 15432521     EISSN: 21507376     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. ICH, Q1A(R2) Stability Testing of New Drug Substances and Products (Geneva, Feb. 2003).
2. ICH, Q1B Stability Testing: Photostability Testing of New Drug Substances and Products (Geneva, Nov. 1996).
3. H. Brittain, Analytical Profiles of Drug Substances and Excipients (Academic Press, London, 2002).
4. A. Srinivasan and R. Iser, Pharm. Technol. 34 (1), 50-59 (2010).
5. A. Srinivasan, R. Iser, and D. Gill, Pharm. Technol. 34(8), 45-51 (2010).
6. A. Srinivasan, R. Iser, and D. Gill, Pharm. Technol. 35 (2), 58-67 (2011).
7. S. Klick, et al., Pharm.Technol. 29 (2) 48-66 (2005).
8. K. M. Alsante, L. Martin and S. W. Baertschi, Pharm.Technol. 27 (2) 60-72 (2003).
9. D. W. Reynolds, et al., Pharm.Technol. 26 (2), 48-56 (2002).
10. K. M. Alsante et al., Advanced Drug Delivery Reviews 59, 29-37 (2007).
11. FDA, Guidance for Industry on Analytical Procedures and methods Validation Chemistry, Manufacturing, and Controls Documentation (draft) (Rockville, MD, Aug. 2000).
12. ICH, Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances (Geneva, Oct. 1999).
13. ICH, Q3A(R2) Impurities in New Drug Substances (Geneva, Oct. 2006).
14. ICH, Q3B(R2) Impurities in New Drug Products (Geneva, June 2006).
15. FDA, Guidance for Industry ANDAs: Impurities in Drug Substances (draft), (Rockville, MD, Aug. 2005).
16. FDA, Guidance for Industry ANDAs: Impurities in Drug Products (draft) (Rockville, MD, Nov. 2010).
17. EMA, Guideline on the Limits of Genotoxic Impurities, Committee for Medical Products for Human Use (CHMP) (Doc. Ref EMA/ CHMP/QWP/251344/2006) (Jan. 1, 2007).
18. K. A. Conners et al., Chemical Stability of Pharmaceuticals, Wiley and Sons, New York, New York, 2nd Ed., p. 19 (1986). PT